Prevalence of anemia in chronic kidney disease in the United States

Melissa E Stauffer, Tao Fan, Melissa E Stauffer, Tao Fan

Abstract

Anemia is one of the many complications of chronic kidney disease (CKD). However, the current prevalence of anemia in CKD patients in the United States is not known. Data from the National Health and Nutrition Examination Survey (NHANES) in 2007-2008 and 2009-2010 were used to determine the prevalence of anemia in subjects with CKD. The analysis was limited to adults aged >18 who participated in both the interview and exam components of the survey. Three outcomes were assessed: the prevalence of CKD, the prevalence of anemia in subjects with CKD, and the self-reported treatment of anemia. CKD was classified into 5 stages based on the glomerular filtration rate and evidence of kidney damage, in accordance with the guidelines of the National Kidney Foundation. Anemia was defined as serum hemoglobin levels ≤12 g/dL in women and ≤13 g/dL in men. We found that an estimated 14.0% of the US adult population had CKD in 2007-2010. Anemia was twice as prevalent in people with CKD (15.4%) as in the general population (7.6%). The prevalence of anemia increased with stage of CKD, from 8.4% at stage 1 to 53.4% at stage 5. A total of 22.8% of CKD patients with anemia reported being treated for anemia within the previous 3 months-14.6% of patients at CKD stages 1-2 and 26.4% of patients at stages 3-4. These results update our knowledge of the prevalence and treatment of anemia in CKD in the United States.

Conflict of interest statement

Competing Interests: The authors have the following interests. This study was funded by Merck & Co., Inc., the employer of Tao Fan. Melissa Stauffer received remuneration from SCRIBCO to perform the work described in this manuscript. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

References

    1. National Kidney Foundation (2002) K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 39: S1–S266.
    1. Zhang QL, Rothenbacher D (2008) Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8: 117.
    1. Smith RE, Jr. (2010) The clinical and economic burden of anemia. Am J Manag Care 16 Suppl Issues: S59–66.
    1. National Kidney Foundation (2006) KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47: S11–145.
    1. Mehdi U, Toto RD (2009) Anemia, diabetes, and chronic kidney disease. Diabetes Care 32: 1320–1326.
    1. Herzog CA, Muster HA, Li S, Collins AJ (2004) Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 10: 467–472.
    1. van Nooten FE, Green J, Brown R, Finkelstein FO, Wish J (2010) Burden of illness for patients with non-dialysis chronic kidney disease and anemia in the United States: review of the literature. J Med Econ 13: 241–256.
    1. Bowling CB, Inker LA, Gutierrez OM, Allman RM, Warnock DG, et al. (2011) Age-specific associations of reduced estimated glomerular filtration rate with concurrent chronic kidney disease complications. Clin J Am Soc Nephrol 6: 2822–2828.
    1. Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW (2005) Economic burden of anemia in an insured population. J Manag Care Pharm 11: 565–574.
    1. Hsu CY, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13: 504–510.
    1. Clase CM, Kiberd BA, Garg AX (2007) Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract 105: c178–184.
    1. Fishbane S, Pollack S, Feldman HI, Joffe MM (2009) Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988–2004. Clin J Am Soc Nephrol 4: 57–61.
    1. Stevens LA, Li S, Wang C, Huang C, Becker BN, et al. (2010) Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 55: S23–33.
    1. National Kidney Foundation. Frequently Asked Questions about GFR Estimates. . Accessed August 1, 2012.
    1. National Anemia Action Council. Anemia & Kidney Disease. . Accessed August 1, 2012.
    1. World Health Organization (2001) Iron Deficiency Anaemia: Assessment, Prevention, and Control. Geneva, Switzerland. Available at: .
    1. Centers for Disease Control and Prevention. (2012) National Health and Nutrition Examination Survey Analytic and Reporting Guidelines. . Accessed October 18, 2012.
    1. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1–12.
    1. Centers for Disease Control and Prevention (2007) Prevalence of Chronic Kidney Disease and Associated Risk Factors – United States, 1999–2004. Morbidity and Mortality Weekly Report 58: 161–165.
    1. Coresh J, Byrd-Holt D, Astor BC, Briggs JP, Eggers PW, et al. (2005) Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 16: 180–188.
    1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, et al. (2007) Prevalence of chronic kidney disease in the United States. JAMA 298: 2038–2047.
    1. Brown WW, Peters RM, Ohmit SE, Keane WF, Collins A, et al. (2003) Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 42: 22–35.
    1. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, et al. (2011) Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 57: S9–16.
    1. Moossavi S, Freedman BI (2009) Treating anemia with erythropoiesis-stimulating agents: effects on quality of life. Arch Intern Med 169: 1100–1101.
    1. Robinson B, Artz AS, Culleton B, Critchlow C, Sciarra A, et al. (2007) Prevalence of anemia in the nursing home: contribution of chronic kidney disease. J Am Geriatr Soc 55: 1566–1570.
    1. Rasu RS, Manley HJ, Crawford T, Balkrishnan R (2007) Undertreatment of anemia in patients with chronic kidney disease in the United States: analysis of national outpatient survey data. Clin Ther 29: 1524–1534.
    1. Lenz O, Fornoni A (2006) Chronic kidney disease care delivered by US family medicine and internal medicine trainees: results from an online survey. BMC Med 4: 30.
    1. Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, et al. (2010) Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. Nephrol Dial Transplant 25: 2237–2244.
    1. Snyder JJ, Foley RN, Collins AJ (2009) Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999–2004. Am J Kidney Dis 53: 218–228.
    1. Agarwal AK (2006) Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. J Am Med Dir Assoc 7: S7–S12; quiz S17–21.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner